"The panel urges clinicians to consider the pretest probability of AD pathology for each patient when deciding whether or not to use a BBM test,” and not as a standalone diagnostic tool.
Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Research reveals significant associations between environmental microplastic pollution and increased rates of hypertension, diabetes, and stroke across U.S. coastal communities, with pollution levels ranking among top predictors for chronic disease prevalence.
A new stem cell–derived islet therapy showed insulin independence, restored beta-cell function, and prevented severe hypoglycemia in type 1 diabetes, based on interim results presented at the ADA’s 85th Scientific Sessions.